Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.
ABSTRACT: The two known receptors, CXCR4 and CXCR7, for the chemokine stromal cell-derived factor-1 (SDF1) play a role in the development and metastasis of multiple cancers, including melanoma. CXCR4 ...
ABSTRACT: The two known receptors, CXCR4 and CXCR7, for the chemokine stromal cell-derived factor-1 (SDF1) play a role in the development and metastasis of multiple cancers, including melanoma. CXCR4 ...
Division of Medicinal Chemistry, Amsterdam Institute of Molecular and Life Sciences, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands ...
DONGTAN, KOREA, February 13, 2025 - iLeadBMS, a spin-off biotech from Ildong Pharmaceutical Group, announced that it has received a notification from the US Food and Drug Administration (FDA) that its ...
The role of CXC chemokine receptors in tumors has been an increasingly researched focus in recent years. However, significant prognostic values of CXCR members in acute myeloid leukemia are yet to be ...
The therapeutic potential of mesenchymal stem cells (MSCs) has been investigated in many preclinical and clinical studies. This potential is dominantly based on the immunosuppressive properties of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results